PBLS – Parabilis Medicines Inc

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=PBLS#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

PBLS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.66

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

1.73

EPS Last/This Y

-0.77

EPS This/Next Y

0.39

Price

24.47

Target Price

41.4

Analyst Recom

Performance Q

-23.19

Upside

N/A

Beta

Ticker: PBLS

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-25	PBLS	31.2	0.44	1.43	554
2026-09-28	PBLS	32.54	0.47	5.00	560
2026-09-29	PBLS	31.89	0.50	0.00	570
2026-09-30	PBLS	32.73	0.50	0.00	570
2026-10-01	PBLS	30.39	0.51	999.99	565
2026-10-02	PBLS	30.29	0.50	999.99	561
2026-10-05	PBLS	29.5	0.49	1.50	557
2026-10-06	PBLS	28.9	0.51	0.07	566
2026-10-07	PBLS	28.78	0.51	0.25	568
2026-10-08	PBLS	28.12	0.51	5.00	567
2026-10-09	PBLS	27.49	0.52	0.00	572
2026-10-12	PBLS	28.94	0.52	0.00	572
2026-10-13	PBLS	26.79	0.52	0.00	572
2026-10-14	PBLS	25.9	0.52	0.67	574
2026-10-15	PBLS	25.16	0.52	999.99	582
2026-10-16	PBLS	22.69	0.52	999.99	582
2026-10-19	PBLS	25.34	0.29	0.35	409
2026-10-20	PBLS	27.12	0.27	0.00	433
2026-10-21	PBLS	27.86	0.25	0.00	468
2026-10-22	PBLS	26.93	0.25	0.00	479
2026-10-23	PBLS	24.43	0.24	0.30	484
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-25	PBLS	31.15	-	-	-2.58
2026-09-28	PBLS	32.60	-	-	-2.58
2026-09-29	PBLS	31.89	-	-	-2.58
2026-09-30	PBLS	32.26	-	-	-2.58
2026-10-01	PBLS	30.49	-	-	-2.58
2026-10-02	PBLS	30.28	-	-	-2.58
2026-10-05	PBLS	29.51	-	-	-2.58
2026-10-06	PBLS	28.89	-	-	-2.58
2026-10-07	PBLS	28.82	-	-	-2.58
2026-10-08	PBLS	28.07	-	-	-2.58
2026-10-09	PBLS	27.53	-	-	-2.58
2026-10-12	PBLS	28.96	-	-	-2.58
2026-10-13	PBLS	26.80	-	-	-2.58
2026-10-14	PBLS	25.90	-	-	-2.58
2026-10-15	PBLS	25.19	-	-	-2.58
2026-10-16	PBLS	22.74	-	-	-2.58
2026-10-19	PBLS	25.34	-	-	-2.58
2026-10-20	PBLS	25.34	-	-	-2.58
2026-10-21	PBLS	27.06	-	-	-2.58
2026-10-22	PBLS	26.90	-	-	-2.58
2026-10-23	PBLS	24.47	-	-	-2.58
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-25	PBLS	91.17	113.62	7.86
2026-09-28	PBLS	91.17	113.62	7.86
2026-09-29	PBLS	91.17	113.62	7.86
2026-09-30	PBLS	91.17	113.62	7.86
2026-10-01	PBLS	91.17	113.62	7.86
2026-10-02	PBLS	91.17	113.62	7.86
2026-10-05	PBLS	91.17	112.37	7.86
2026-10-06	PBLS	91.17	112.37	7.86
2026-10-07	PBLS	91.17	112.37	7.86
2026-10-08	PBLS	91.17	112.37	7.86
2026-10-09	PBLS	91.17	112.37	7.86
2026-10-12	PBLS	91.17	120.57	10.66
2026-10-13	PBLS	91.17	120.57	10.66
2026-10-14	PBLS	91.17	120.57	10.66
2026-10-15	PBLS	91.17	120.57	10.66
2026-10-16	PBLS	91.17	120.57	10.66
2026-10-19	PBLS	91.18	120.65	10.66
2026-10-20	PBLS	91.18	120.65	10.66
2026-10-21	PBLS	91.17	120.65	10.66
2026-10-22	PBLS	91.17	120.65	10.66
2026-10-23	PBLS	91.17	120.65	10.66
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=PBLS 589 360 ]

Last Quarter Act. EPS

-2.13

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.4

Insider Transactions

91.17

Institutional Transactions

120.65

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

42.4

Max Drawdown 5-Year %

Target Price

41.4

P/E

Forward P/E

PEG

P/S

P/B

2.88

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

-2.58

EPS Next Y. (Est.)

-2.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.28

Return on Equity vs Sector %

-47.7

Return on Equity vs Industry %

-28.2

EPS 1 7Days Diff

-0.9

EPS 1 30Days Diff

-0.92

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=PBLS 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=PBLS 589 450 ]

◆ PBLS Healthcare

$24.44

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

13/25

Volume

0/15

Valuation

8/20

TP/AR

6/10

Options

5/10

RSI

Range 1M

14%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

4/30

Estimates

6/20

Inst/Vol

8/15

Options

7/10

EPS Yr

EPS NY

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +69.4% upside

Quality

3/30

Valuation

14/30

Growth

2/25

Stability

7/10

LT Trend

0/5

Upside

+69.4%

Quality

PBLS — P/E HistoricalBiotechnology

Parabilis Medicines, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 145

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

PBLS

Latest News

—

Caricamento notizie per PBLS…

stock quote shares PBLS – Parabilis Medicines Inc Stock Price stock today

news today PBLS – Parabilis Medicines Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PBLS – Parabilis Medicines Inc yahoo finance google finance

stock history PBLS – Parabilis Medicines Inc invest stock market

stock prices PBLS premarket after hours

ticker PBLS fair value insiders trading

ROIV – Roivant Sciences Ltd

ROIV — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

7.5

Margin Of Safety %

Put/Call OI Ratio

0.48

EPS Next Q Diff

0.04

EPS Last/This Y

-1.15

EPS This/Next Y

-0.14

Price

36.49

Target Price

48.91

Analyst Recom

1.4

Performance Q

5.1

Upside

-115.7%

Beta

1.23

Ticker: ROIV

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-25	ROIV	35.8	0.52	0.15	74025
2026-09-28	ROIV	37	0.52	0.06	74122
2026-09-29	ROIV	36.51	0.52	1.31	74260
2026-09-30	ROIV	36.58	0.52	0.04	74339
2026-10-01	ROIV	35.5	0.52	0.00	74403
2026-10-02	ROIV	35.69	0.52	0.31	74465
2026-10-05	ROIV	35.8	0.52	0.19	74455
2026-10-06	ROIV	35.53	0.52	1.60	74508
2026-10-07	ROIV	34.75	0.49	0.00	77358
2026-10-08	ROIV	34.22	0.47	0.01	79358
2026-10-09	ROIV	35.42	0.47	0.00	79264
2026-10-12	ROIV	34.61	0.47	0.00	79195
2026-10-13	ROIV	33.37	0.46	0.32	80716
2026-10-14	ROIV	33.62	0.46	0.07	80723
2026-10-15	ROIV	34.04	0.46	0.80	80709
2026-10-16	ROIV	33.52	0.46	0.10	80719
2026-10-19	ROIV	34.68	0.46	0.22	79712
2026-10-20	ROIV	34.92	0.46	0.13	79719
2026-10-21	ROIV	36.81	0.46	0.85	79757
2026-10-22	ROIV	37.44	0.48	0.00	81934
2026-10-23	ROIV	36.53	0.48	0.04	81831
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-25	ROIV	35.81	-63.3	-	-1.58
2026-09-28	ROIV	37.00	-63.3	-	-1.58
2026-09-29	ROIV	36.51	-63.3	-	-1.58
2026-09-30	ROIV	36.53	-63.3	-	-1.58
2026-10-01	ROIV	35.50	-63.3	-	-1.58
2026-10-02	ROIV	35.72	-63.3	-	-1.58
2026-10-05	ROIV	35.82	-63.3	-	-1.58
2026-10-06	ROIV	35.54	-63.3	-	-1.58
2026-10-07	ROIV	34.75	-63.3	-	-1.58
2026-10-08	ROIV	34.22	-63.3	-	-1.58
2026-10-09	ROIV	35.42	-63.3	-	-1.58
2026-10-12	ROIV	34.59	-63.3	-	-1.58
2026-10-13	ROIV	33.36	-63.3	-	-1.58
2026-10-14	ROIV	33.62	-63.3	-	-1.58
2026-10-15	ROIV	34.05	-63.3	-	-1.58
2026-10-16	ROIV	33.52	-63.3	-	-1.58
2026-10-19	ROIV	34.71	-63.3	-	-1.58
2026-10-20	ROIV	34.71	-63.3	-	-1.58
2026-10-21	ROIV	34.93	-63.3	-	-1.58
2026-10-22	ROIV	37.44	-63.3	-	-1.58
2026-10-23	ROIV	36.49	-63.3	-	-1.58
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-25	ROIV	-3.85	3.87	6.90
2026-09-28	ROIV	-3.85	3.91	6.90
2026-09-29	ROIV	-3.85	3.91	6.90
2026-09-30	ROIV	-3.85	3.91	6.90
2026-10-01	ROIV	-3.82	3.91	6.90
2026-10-02	ROIV	-3.82	3.91	6.90
2026-10-05	ROIV	-3.91	3.91	6.90
2026-10-06	ROIV	-3.92	3.91	6.90
2026-10-07	ROIV	-3.92	3.91	6.90
2026-10-08	ROIV	-3.92	3.91	6.90
2026-10-09	ROIV	-3.92	3.91	6.90
2026-10-12	ROIV	-3.92	3.89	7.50
2026-10-13	ROIV	-3.92	3.89	7.50
2026-10-14	ROIV	-3.92	3.89	7.50
2026-10-15	ROIV	-3.92	3.89	7.50
2026-10-16	ROIV	-3.92	3.89	7.50
2026-10-19	ROIV	-3.92	3.89	7.50
2026-10-20	ROIV	-3.92	3.89	7.50
2026-10-21	ROIV	-3.78	3.89	7.50
2026-10-22	ROIV	-3.78	3.89	7.50
2026-10-23	ROIV	-3.78	3.89	7.50
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.45

Avg. EPS Est. Current Quarter

-0.45

Avg. EPS Est. Next Quarter

-0.41

Insider Transactions

-3.78

Institutional Transactions

3.89

Beta

1.23

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.1

Max Drawdown 5-Year %

-79.2

Target Price

48.91

P/E

Forward P/E

PEG

P/S

3500.34

P/B

6.23

P/Free Cash Flow

EPS

-0.44

Average EPS Est. Cur. Y

-1.58

EPS Next Y. (Est.)

-1.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3534.96

Relative Volume

1.11

Return on Equity vs Sector %

-31.9

Return on Equity vs Industry %

-12.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ ROIV Healthcare

$36.49

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

4/20

Pullback

5/25

Volume

4/15

Valuation

7/20

TP/AR

4/10

Options

6/10

RSI

53.4

Range 1M

64.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

8/30

Estimates

3/20

Inst/Vol

8/15

Options

9/10

EPS Yr

-155%

EPS NY

52W%

75.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +34% upside

Quality

6/30

Valuation

8/30

Growth

5/25

Stability

7/10

LT Trend

0/5

Upside

+34%

Quality

ROIV — P/E HistoricalBiotechnology

Roivant Sciences Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 721

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

ROIV

Latest News

—

Caricamento notizie per ROIV…

stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today

news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance

stock history ROIV – Roivant Sciences Ltd invest stock market

stock prices ROIV premarket after hours

ticker ROIV fair value insiders trading

RNAM – Avidity Biosciences Inc

ONC – BeOne Medicines Ltd ADR

ONC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.86

Margin Of Safety %

Put/Call OI Ratio

0.58

EPS Next Q Diff

-0.5

EPS Last/This Y

-0.42

EPS This/Next Y

2.61

Price

377.94

Target Price

437.83

Analyst Recom

1.27

Performance Q

15.87

Upside

-47.3%

Beta

0.64

Ticker: ONC

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-25	ONC	361.18	0.66	25.33	1389
2026-09-28	ONC	366.64	0.75	0.67	1468
2026-09-29	ONC	365.5	0.75	0.07	1482
2026-09-30	ONC	366.06	0.74	0.03	1494
2026-10-01	ONC	358.88	0.72	0.29	1518
2026-10-02	ONC	358.44	0.71	1.00	1528
2026-10-05	ONC	361.79	0.72	0.87	1543
2026-10-06	ONC	362.97	0.73	0.15	1564
2026-10-07	ONC	363.78	0.72	0.50	1584
2026-10-08	ONC	350.08	0.72	0.52	1584
2026-10-09	ONC	354.42	0.68	0.29	1558
2026-10-12	ONC	350.44	0.63	0.18	1536
2026-10-13	ONC	349.25	0.63	0.40	1556
2026-10-14	ONC	351.57	0.62	0.25	1560
2026-10-15	ONC	374.3	0.62	0.03	1543
2026-10-16	ONC	369.31	0.67	0.69	1476
2026-10-19	ONC	370.36	0.74	0.36	1333
2026-10-20	ONC	384.79	0.74	0.95	1354
2026-10-21	ONC	386.37	0.75	0.62	1410
2026-10-22	ONC	382.59	0.75	0.06	1448
2026-10-23	ONC	377.95	0.58	0.63	1725
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-25	ONC	363.02	66.9	555.0	7.60
2026-09-28	ONC	366.70	66.9	525.2	7.60
2026-09-29	ONC	367.15	66.9	519.5	7.60
2026-09-30	ONC	366.71	66.9	533.0	7.60
2026-10-01	ONC	358.61	66.9	447.2	7.60
2026-10-02	ONC	356.33	70.1	663.6	7.62
2026-10-05	ONC	361.42	70.1	783.8	7.62
2026-10-06	ONC	362.00	70.1	504.2	7.62
2026-10-07	ONC	363.96	70.1	499.9	7.62
2026-10-08	ONC	349.25	70.1	458.7	7.62
2026-10-09	ONC	354.35	70.1	516.1	7.62
2026-10-12	ONC	350.40	72.3	521.9	7.62
2026-10-13	ONC	350.86	72.3	508.3	7.64
2026-10-14	ONC	351.45	72.3	497.7	7.64
2026-10-15	ONC	375.01	72.3	603.4	7.64
2026-10-16	ONC	368.56	72.3	565.0	7.64
2026-10-19	ONC	370.04	72.3	503.2	7.64
2026-10-20	ONC	370.04	72.3	503.2	7.64
2026-10-21	ONC	384.79	72.3	565.9	7.64
2026-10-22	ONC	382.27	72.3	503.4	7.64
2026-10-23	ONC	377.94	72.3	502.6	7.64
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-25	ONC	-64.15	1.05	1.65
2026-09-28	ONC	-64.15	1.10	1.65
2026-09-29	ONC	-64.15	1.10	1.65
2026-09-30	ONC	-64.15	1.10	1.65
2026-10-01	ONC	-64.85	1.10	1.65
2026-10-02	ONC	-64.85	1.10	1.65
2026-10-05	ONC	-64.88	2.01	1.65
2026-10-06	ONC	-64.88	2.01	1.65
2026-10-07	ONC	-64.88	2.01	1.65
2026-10-08	ONC	-64.88	2.01	1.65
2026-10-09	ONC	-64.88	2.01	1.65
2026-10-12	ONC	-64.87	1.94	1.86
2026-10-13	ONC	-64.87	1.94	1.86
2026-10-14	ONC	-64.87	1.94	1.86
2026-10-15	ONC	-64.87	1.94	1.86
2026-10-16	ONC	-65.55	1.94	1.86
2026-10-19	ONC	-65.55	1.94	1.86
2026-10-20	ONC	-65.55	1.94	1.86
2026-10-21	ONC	-65.55	1.94	1.86
2026-10-22	ONC	-65.55	1.94	1.86
2026-10-23	ONC	-65.55	1.94	1.86
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

2.05

Avg. EPS Est. Current Quarter

1.88

Avg. EPS Est. Next Quarter

1.55

Insider Transactions

-65.55

Institutional Transactions

1.94

Beta

0.64

Average Sales Estimate Current Quarter

1752

Average Sales Estimate Next Quarter

1794

Fair Value

412.94

Quality Score

Growth Score

Sentiment Score

100

Actual DrawDown %

3.7

Max Drawdown 5-Year %

-68.9

Target Price

437.83

P/E

66.36

Forward P/E

37.75

PEG

0.52

P/S

6.41

P/B

8.25

P/Free Cash Flow

29.53

EPS

5.69

Average EPS Est. Cur. Y

7.64

EPS Next Y. (Est.)

10.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.7

Relative Volume

0.8

Return on Equity vs Sector %

-12.9

Return on Equity vs Industry %

6.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

502.6

◆ ONC Healthcare

$377.63

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

10/25

Volume

7/15

Valuation

12/20

TP/AR

2/10

Options

6/10

RSI

58.9

Range 1M

76.8%

Sup Dist

0.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

28/30

Estimates

6/20

Inst/Vol

6/15

Options

8/10

EPS Yr

176.6%

EPS NY

37.5%

52W%

91.7%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +3.5% upside

Quality

17/30

Valuation

8/30

Growth

21/25

Stability

5/10

LT Trend

1/5

Upside

+3.5%

Quality

MoS

ONC — P/E HistoricalBiotechnology

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

COGT – Cogent Biosciences Inc

COGT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.49

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

-0.06

EPS Last/This Y

-0.05

EPS This/Next Y

1.04

Price

31.18

Target Price

55.82

Analyst Recom

1.17

Performance Q

-22.82

Upside

-373.6%

Beta

0.35

Ticker: COGT

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-25	COGT	32.35	0.10	0.02	27822
2026-09-28	COGT	31.87	0.10	0.04	28611
2026-09-29	COGT	31.69	0.10	0.09	28597
2026-09-30	COGT	32.03	0.10	0.28	28669
2026-10-01	COGT	31.62	0.10	0.03	28640
2026-10-02	COGT	31.02	0.10	0.11	28646
2026-10-05	COGT	30.87	0.10	0.47	28797
2026-10-06	COGT	30.37	0.11	0.15	29042
2026-10-07	COGT	30.14	0.11	0.10	28792
2026-10-08	COGT	30.1	0.12	0.29	28590
2026-10-09	COGT	31	0.12	0.46	28774
2026-10-12	COGT	29.79	0.12	5.42	28761
2026-10-13	COGT	28.09	0.11	3.87	28712
2026-10-14	COGT	28.16	0.12	1.60	29788
2026-10-15	COGT	29.59	0.12	0.94	29678
2026-10-16	COGT	29.54	0.12	1.00	29909
2026-10-19	COGT	30.02	0.11	0.02	26764
2026-10-20	COGT	31.24	0.11	0.12	26960
2026-10-21	COGT	31.47	0.12	0.06	28241
2026-10-22	COGT	31.32	0.12	0.03	28080
2026-10-23	COGT	31.19	0.12	0.13	28121
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-25	COGT	32.34	-9.5	-	-2.21
2026-09-28	COGT	31.88	-9.5	-	-2.21
2026-09-29	COGT	31.66	-9.5	-	-2.21
2026-09-30	COGT	32.03	-9.5	-	-2.21
2026-10-01	COGT	31.60	-9.5	-	-2.21
2026-10-02	COGT	31.02	-9.5	-	-2.21
2026-10-05	COGT	30.88	-9.5	-	-2.21
2026-10-06	COGT	30.36	-9.5	-	-2.21
2026-10-07	COGT	30.14	-9.5	-	-2.21
2026-10-08	COGT	30.07	-9.5	-	-2.21
2026-10-09	COGT	31.02	-9.5	-	-2.21
2026-10-12	COGT	29.78	-9.5	-	-2.21
2026-10-13	COGT	28.09	-9.5	-	-2.21
2026-10-14	COGT	28.16	-9.5	-	-2.21
2026-10-15	COGT	29.51	-9.5	-	-2.21
2026-10-16	COGT	29.53	-9.5	-	-2.21
2026-10-19	COGT	30.01	-9.5	-	-2.21
2026-10-20	COGT	30.01	-9.5	-	-2.21
2026-10-21	COGT	31.22	-9.5	-	-2.21
2026-10-22	COGT	31.32	-9.5	-	-2.21
2026-10-23	COGT	31.18	-9.5	-	-2.21
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-25	COGT	-28.43	4.70	11.63
2026-09-28	COGT	-28.43	4.71	11.63
2026-09-29	COGT	-28.43	4.71	11.63
2026-09-30	COGT	-28.43	4.71	11.63
2026-10-01	COGT	-0.26	4.71	11.63
2026-10-02	COGT	-0.26	4.71	11.63
2026-10-05	COGT	-0.26	4.46	11.63
2026-10-06	COGT	-0.26	4.46	11.63
2026-10-07	COGT	-0.26	4.46	11.63
2026-10-08	COGT	-0.26	4.46	11.63
2026-10-09	COGT	-0.26	4.46	11.63
2026-10-12	COGT	-0.26	4.60	12.49
2026-10-13	COGT	-0.26	4.60	12.49
2026-10-14	COGT	-0.26	4.60	12.49
2026-10-15	COGT	-0.26	4.60	12.49
2026-10-16	COGT	-0.26	4.60	12.49
2026-10-19	COGT	-0.26	4.68	12.49
2026-10-20	COGT	-0.26	4.68	12.49
2026-10-21	COGT	-0.26	4.68	12.49
2026-10-22	COGT	-0.26	4.68	12.49
2026-10-23	COGT	-0.26	4.68	12.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.52

Avg. EPS Est. Current Quarter

-0.55

Avg. EPS Est. Next Quarter

-0.58

Insider Transactions

-0.26

Institutional Transactions

4.68

Beta

0.35

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

28.7

Max Drawdown 5-Year %

-76.3

Target Price

55.82

P/E

Forward P/E

PEG

P/S

P/B

11.46

P/Free Cash Flow

EPS

-2.44

Average EPS Est. Cur. Y

-2.21

EPS Next Y. (Est.)

-1.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.9

Return on Equity vs Sector %

-96.5

Return on Equity vs Industry %

-76.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ COGT Healthcare

$31.21

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

18/20

Pullback

15/25

Volume

7/15

Valuation

10/20

TP/AR

2/10

Options

8/10

RSI

49.4

Range 1M

65.3%

Sup Dist

1.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

14/30

Estimates

0/20

Inst/Vol

6/15

Options

8/10

EPS Yr

-2.6%

EPS NY

50.8%

52W%

57.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +78.9% upside

Quality

2/30

Valuation

12/30

Growth

10/25

Stability

8/10

LT Trend

3/5

Upside

+78.9%

Quality

COGT — P/E HistoricalBiotechnology

Cogent Biosciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

COGT

Latest News

—

Caricamento notizie per COGT…

stock quote shares COGT – Cogent Biosciences Inc Stock Price stock today

news today COGT – Cogent Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch COGT – Cogent Biosciences Inc yahoo finance google finance

stock history COGT – Cogent Biosciences Inc invest stock market

stock prices COGT premarket after hours

ticker COGT fair value insiders trading

CGON – Cg Oncology Inc

CGON — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.67

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

0.06

EPS Last/This Y

-1.15

EPS This/Next Y

0.21

Price

61.68

Target Price

91.08

Analyst Recom

1.13

Performance Q

-16.06

Upside

-156.9%

Beta

0.33

Ticker: CGON

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-25	CGON	67.18	0.12	1.61	32440
2026-09-28	CGON	69.67	0.13	0.01	32701
2026-09-29	CGON	70.58	0.13	0.02	32789
2026-09-30	CGON	70.92	0.14	0.38	31986
2026-10-01	CGON	68.28	0.14	0.19	32386
2026-10-02	CGON	67.43	0.14	1.62	32514
2026-10-05	CGON	68.71	0.16	0.36	32964
2026-10-06	CGON	63.63	0.17	0.03	35125
2026-10-07	CGON	62.38	0.17	0.44	35657
2026-10-08	CGON	63.12	0.18	0.60	36537
2026-10-09	CGON	63.84	0.19	0.45	36833
2026-10-12	CGON	63.15	0.21	0.61	39452
2026-10-13	CGON	62.45	0.23	0.51	41602
2026-10-14	CGON	61.83	0.23	1.46	42307
2026-10-15	CGON	61.86	0.23	1.00	42485
2026-10-16	CGON	59.88	0.23	0.53	43054
2026-10-19	CGON	60.02	0.20	0.09	34989
2026-10-20	CGON	61.91	0.21	0.49	36623
2026-10-21	CGON	62.22	0.22	0.48	38333
2026-10-22	CGON	62.51	0.23	4.56	38581
2026-10-23	CGON	61.66	0.26	2.94	39862
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-25	CGON	67.20	-42.0	-10.0	-3.23
2026-09-28	CGON	69.75	-42.0	-	-3.23
2026-09-29	CGON	70.56	-42.0	-	-3.23
2026-09-30	CGON	70.92	-42.0	-	-3.23
2026-10-01	CGON	68.33	-42.0	-	-3.23
2026-10-02	CGON	67.36	-42.0	-	-3.23
2026-10-05	CGON	68.67	-42.0	-	-3.23
2026-10-06	CGON	63.55	-42.0	-	-3.23
2026-10-07	CGON	62.38	-42.0	-	-3.23
2026-10-08	CGON	63.27	-42.0	-	-3.23
2026-10-09	CGON	63.86	-42.0	-	-3.23
2026-10-12	CGON	63.13	-42.0	-	-3.23
2026-10-13	CGON	62.45	-42.0	-	-3.23
2026-10-14	CGON	61.90	-42.0	-	-3.23
2026-10-15	CGON	61.91	-42.0	-	-3.23
2026-10-16	CGON	59.87	-42.0	-	-3.23
2026-10-19	CGON	59.96	-42.0	-	-3.23
2026-10-20	CGON	59.96	-42.0	-	-3.23
2026-10-21	CGON	61.92	-42.0	-	-3.23
2026-10-22	CGON	62.56	-42.0	-	-3.23
2026-10-23	CGON	61.68	-42.0	-	-3.23
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-25	CGON	1.08	3.00	19.05
2026-09-28	CGON	1.08	2.97	19.05
2026-09-29	CGON	1.08	2.97	19.05
2026-09-30	CGON	1.08	2.97	19.05
2026-10-01	CGON	1.08	2.97	19.05
2026-10-02	CGON	1.08	2.97	19.05
2026-10-05	CGON	1.08	2.92	19.05
2026-10-06	CGON	1.08	2.92	19.05
2026-10-07	CGON	1.08	2.92	19.05
2026-10-08	CGON	1.08	2.92	19.05
2026-10-09	CGON	1.08	2.92	19.05
2026-10-12	CGON	1.08	3.05	17.67
2026-10-13	CGON	1.08	3.05	17.67
2026-10-14	CGON	1.08	3.05	17.67
2026-10-15	CGON	1.08	3.05	17.67
2026-10-16	CGON	1.08	3.05	17.67
2026-10-19	CGON	1.08	3.05	17.67
2026-10-20	CGON	1.08	3.05	17.67
2026-10-21	CGON	1.13	3.05	17.67
2026-10-22	CGON	1.13	3.05	17.67
2026-10-23	CGON	1.13	3.05	17.67
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.9

Avg. EPS Est. Current Quarter

-0.81

Avg. EPS Est. Next Quarter

-0.84

Insider Transactions

1.13

Institutional Transactions

3.05

Beta

0.33

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

23.8

Max Drawdown 5-Year %

Target Price

91.08

P/E

Forward P/E

PEG

P/S

878.01

P/B

5.3

P/Free Cash Flow

EPS

-2.7

Average EPS Est. Cur. Y

-3.23

EPS Next Y. (Est.)

-3.02

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3602.68

Relative Volume

1.22

Return on Equity vs Sector %

-47.4

Return on Equity vs Industry %

-27.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

◆ CGON Healthcare

$61.71

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

23/25

Volume

4/15

Valuation

10/20

TP/AR

2/10

Options

4/10

RSI

37.6

Range 1M

16.6%

Sup Dist

0.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

5/30

Estimates

1/20

Inst/Vol

7/15

Options

4/10

EPS Yr

-59.5%

EPS NY

5.6%

52W%

57.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +47.6% upside

Quality

2/30

Valuation

10/30

Growth

2/25

Stability

9/10

LT Trend

3/5

Upside

+47.6%

Quality

CGON — P/E HistoricalBiotechnology

CG Oncology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 142

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

CGON

Latest News

—

Caricamento notizie per CGON…

stock quote shares CGON – Cg Oncology Inc Stock Price stock today

news today CGON – Cg Oncology Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch CGON – Cg Oncology Inc yahoo finance google finance

stock history CGON – Cg Oncology Inc invest stock market

stock prices CGON premarket after hours

ticker CGON fair value insiders trading

No more stocks to show

PBLS – Parabilis Medicines Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PBLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

ROIV – Roivant Sciences Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ROIV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y